Desquinolinyl Lenvatinib CAS 796848-79-8 Purity >99.0% (HPLC) Lenvatinib Mesylate Intermediate Factory
Ruifu Chemical Supply Lenvatinib Mesylate Intermediates With High Purity
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib; 1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Chemical Name | 1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea |
Synonyms | Desquinolinyl Lenvatinib; Lenvatinib Impurity 16; Lenvatinib Desquinolinyl Impurity; Lenvatinib Impurity LFS-A; Lenvatinib Mesylate Intermediate Ⅲ; N-(2-Chloro-4-Hydroxyphenyl)-N'-Cyclopropyl-Urea |
CAS Number | 796848-79-8 |
CAT Number | RF-PI1972 |
Stock Status | In Stock, Production Scale Up to Tons |
Molecular Formula | C10H11ClN2O2 |
Molecular Weight | 226.66 |
Boiling Point | 364.6±42.0℃ |
Density | 1.43±0.10 g/cm3 |
Brand | Ruifu Chemical |
Item | Specifications |
Appearance | Off-White to Reddish Brown Solid Powder |
Purity / Analysis Method | >99.0% (HPLC) |
Moisture (K.F) | <0.50% |
Residue on Ignition | <0.20% |
Single Impurity | <0.50% |
Total Impurities | <1.00% |
Heavy Metals | <10ppm |
Infrared Spectrum | Conforms to Structure |
NMR | Conforms to Structure |
Test Standard | Enterprise Standard |
Usage | Intermediate of Lenvatinib Mesylate (CAS: 857890-39-2) |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture
1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea, also known as Desquinolinyl Lenvatinib, (CAS: 796848-79-8) is an intermediate or impurity of Lenvatinib Mesylate (CAS: 857890-39-2). Desquinolinyl Lenvatinib is a metabolite of Lenvatinib Mesylate which is an orally active inhibitor of multiple receptor tyrosine kinases including VEGF, FGF and SCF receptors. Lenvatinib is an anti-cancer drug for the treatment of certain kinds of thyroid cancer, and potentially for other cancers as well. On February 13, 2015, the US FDA approved anticancer drug Lenvatinib for the treatment of thyroid cancer. Lenvatinib is a multi-target enzyme inhibitor, being capable of inhibiting the VEGFR2 and VEGFR3 (vascular endothelial growth factor receptor). The trade name of Lenvatinib is Lenvima.